| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bronchiectasis | 49 | 2021 | 312 | 18.13 | Why? |
| Pulmonary Disease, Chronic Obstructive | 17 | 2018 | 3832 | 2.36 | Why? |
| Bronchodilator Agents | 5 | 2018 | 444 | 1.98 | Why? |
| Pulmonary Medicine | 7 | 2020 | 706 | 1.66 | Why? |
| Macrolides | 4 | 2018 | 369 | 1.62 | Why? |
| Pseudomonas aeruginosa | 8 | 2019 | 652 | 1.60 | Why? |
| Pseudomonas Infections | 6 | 2019 | 425 | 1.47 | Why? |
| Adrenal Cortex Hormones | 8 | 2021 | 6537 | 1.34 | Why? |
| Administration, Inhalation | 9 | 2019 | 1647 | 1.10 | Why? |
| Microbiota | 6 | 2018 | 1240 | 0.98 | Why? |
| Periodicals as Topic | 4 | 2019 | 1492 | 0.89 | Why? |
| Ciprofloxacin | 2 | 2019 | 130 | 0.83 | Why? |
| Anti-Bacterial Agents | 14 | 2019 | 10083 | 0.82 | Why? |
| Disease Progression | 13 | 2021 | 13580 | 0.81 | Why? |
| Leukocyte Elastase | 2 | 2017 | 106 | 0.80 | Why? |
| Respiratory Tract Diseases | 2 | 2019 | 1061 | 0.79 | Why? |
| Phenotype | 4 | 2018 | 4037 | 0.79 | Why? |
| Cystic Fibrosis | 4 | 2018 | 1104 | 0.77 | Why? |
| Sputum | 7 | 2018 | 1720 | 0.73 | Why? |
| Community-Acquired Infections | 4 | 2018 | 2328 | 0.73 | Why? |
| Respiratory System Agents | 1 | 2019 | 63 | 0.72 | Why? |
| Metabolism, Inborn Errors | 1 | 2017 | 51 | 0.69 | Why? |
| Mannose-Binding Lectin | 1 | 2017 | 131 | 0.66 | Why? |
| Endpoint Determination | 1 | 2019 | 344 | 0.66 | Why? |
| Research | 4 | 2021 | 2115 | 0.65 | Why? |
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 94 | 0.60 | Why? |
| Respiratory Therapy | 2 | 2019 | 918 | 0.58 | Why? |
| Inappropriate Prescribing | 1 | 2018 | 284 | 0.56 | Why? |
| Clinical Trials as Topic | 6 | 2019 | 7330 | 0.53 | Why? |
| Health Care Costs | 2 | 2019 | 1007 | 0.52 | Why? |
| Forced Expiratory Volume | 6 | 2018 | 632 | 0.52 | Why? |
| Quality of Life | 10 | 2019 | 9820 | 0.50 | Why? |
| Dysbiosis | 2 | 2017 | 685 | 0.45 | Why? |
| Pneumonia | 3 | 2018 | 5652 | 0.45 | Why? |
| Physical Therapy Modalities | 2 | 2017 | 1090 | 0.44 | Why? |
| Medicare | 1 | 2018 | 1048 | 0.44 | Why? |
| Precision Medicine | 2 | 2018 | 1477 | 0.43 | Why? |
| Pneumonia, Bacterial | 2 | 2018 | 843 | 0.43 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.42 | Why? |
| United Kingdom | 10 | 2021 | 18046 | 0.40 | Why? |
| Respiratory Tract Infections | 4 | 2019 | 6817 | 0.40 | Why? |
| Arthritis, Rheumatoid | 3 | 2019 | 2043 | 0.39 | Why? |
| Europe | 10 | 2020 | 12702 | 0.38 | Why? |
| Humans | 85 | 2021 | 930598 | 0.37 | Why? |
| Cost of Illness | 2 | 2019 | 1903 | 0.37 | Why? |
| Extracellular Traps | 1 | 2017 | 1036 | 0.35 | Why? |
| Research Design | 3 | 2019 | 5830 | 0.35 | Why? |
| Budesonide | 1 | 2009 | 192 | 0.34 | Why? |
| Environmental Exposure | 1 | 2018 | 1558 | 0.34 | Why? |
| Asthma | 4 | 2018 | 4383 | 0.33 | Why? |
| Severity of Illness Index | 12 | 2019 | 48226 | 0.32 | Why? |
| Societies, Medical | 7 | 2020 | 6907 | 0.32 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.30 | Why? |
| Social Support | 1 | 2020 | 3183 | 0.30 | Why? |
| Models, Statistical | 2 | 2020 | 5312 | 0.30 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.30 | Why? |
| Hospitalization | 8 | 2021 | 54280 | 0.29 | Why? |
| Pneumonia, Pneumococcal | 2 | 2018 | 251 | 0.28 | Why? |
| Algorithms | 3 | 2019 | 7346 | 0.27 | Why? |
| Aged | 28 | 2021 | 215776 | 0.25 | Why? |
| Patient Acceptance of Health Care | 2 | 2018 | 5002 | 0.24 | Why? |
| Disease Management | 2 | 2017 | 6841 | 0.24 | Why? |
| Streptococcus pneumoniae | 2 | 2018 | 827 | 0.24 | Why? |
| Prognosis | 4 | 2018 | 32490 | 0.24 | Why? |
| Practice Patterns, Physicians' | 2 | 2018 | 4927 | 0.23 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.22 | Why? |
| Vital Capacity | 3 | 2018 | 399 | 0.22 | Why? |
| Observational Studies as Topic | 2 | 2020 | 1887 | 0.22 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.21 | Why? |
| Middle Aged | 27 | 2021 | 270681 | 0.21 | Why? |
| Respiratory Function Tests | 5 | 2018 | 1755 | 0.21 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.20 | Why? |
| Registries | 2 | 2017 | 12327 | 0.20 | Why? |
| Mycobacterium abscessus | 1 | 2019 | 31 | 0.20 | Why? |
| Air Pollution | 1 | 2018 | 3504 | 0.20 | Why? |
| Residual Volume | 1 | 2018 | 45 | 0.19 | Why? |
| Israel | 2 | 2018 | 2751 | 0.19 | Why? |
| Cross Infection | 2 | 2018 | 8675 | 0.19 | Why? |
| Exercise | 1 | 2019 | 6771 | 0.18 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.18 | Why? |
| Electronic Nose | 1 | 2018 | 36 | 0.18 | Why? |
| Mycobiome | 1 | 2018 | 43 | 0.18 | Why? |
| Male | 28 | 2021 | 367725 | 0.18 | Why? |
| Chronic Disease | 3 | 2017 | 5139 | 0.18 | Why? |
| Microbial Sensitivity Tests | 2 | 2017 | 2886 | 0.18 | Why? |
| Female | 28 | 2021 | 380317 | 0.18 | Why? |
| Cross-Over Studies | 2 | 2018 | 867 | 0.18 | Why? |
| Elastin | 1 | 2017 | 16 | 0.17 | Why? |
| International Cooperation | 3 | 2020 | 3436 | 0.17 | Why? |
| Bacteroidetes | 1 | 2017 | 36 | 0.17 | Why? |
| Proteobacteria | 1 | 2017 | 36 | 0.17 | Why? |
| Birds | 1 | 2020 | 412 | 0.17 | Why? |
| Mucociliary Clearance | 1 | 2018 | 72 | 0.17 | Why? |
| Journal Impact Factor | 1 | 2018 | 134 | 0.17 | Why? |
| Proteoglycans | 1 | 2017 | 130 | 0.16 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.16 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2020 | 10649 | 0.16 | Why? |
| Pulmonologists | 1 | 2017 | 98 | 0.16 | Why? |
| Walk Test | 1 | 2019 | 461 | 0.16 | Why? |
| Spain | 3 | 2020 | 15545 | 0.15 | Why? |
| Muscarinic Antagonists | 1 | 2018 | 176 | 0.15 | Why? |
| Secondary Care | 1 | 2017 | 160 | 0.15 | Why? |
| Adrenergic beta-2 Receptor Agonists | 1 | 2018 | 142 | 0.15 | Why? |
| Logistic Models | 4 | 2018 | 9089 | 0.15 | Why? |
| Prospective Studies | 7 | 2021 | 43301 | 0.15 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.15 | Why? |
| Comorbidity | 5 | 2018 | 34796 | 0.15 | Why? |
| Respiration Disorders | 1 | 2021 | 526 | 0.15 | Why? |
| Nitrogen Dioxide | 1 | 2018 | 488 | 0.15 | Why? |
| Longitudinal Studies | 3 | 2020 | 9893 | 0.15 | Why? |
| Lung | 3 | 2019 | 31049 | 0.14 | Why? |
| Steroids | 1 | 2020 | 904 | 0.14 | Why? |
| Fungi | 1 | 2018 | 471 | 0.14 | Why? |
| Causality | 1 | 2019 | 857 | 0.14 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.14 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.14 | Why? |
| Adult | 18 | 2021 | 244371 | 0.13 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.13 | Why? |
| Cardiotoxicity | 1 | 2017 | 365 | 0.13 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.13 | Why? |
| Review Literature as Topic | 1 | 2017 | 387 | 0.13 | Why? |
| Decision Support Systems, Clinical | 1 | 2019 | 551 | 0.13 | Why? |
| Meta-Analysis as Topic | 1 | 2021 | 1289 | 0.13 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.13 | Why? |
| Glucocorticoids | 1 | 2009 | 4431 | 0.13 | Why? |
| Follow-Up Studies | 4 | 2020 | 17020 | 0.13 | Why? |
| Editorial Policies | 1 | 2018 | 408 | 0.13 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2015 | 8843 | 0.13 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.12 | Why? |
| Pulmonary Aspergillosis | 1 | 2018 | 408 | 0.12 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.12 | Why? |
| Species Specificity | 1 | 2017 | 1356 | 0.12 | Why? |
| Respiration | 1 | 2018 | 729 | 0.12 | Why? |
| Interleukin-17 | 1 | 2017 | 602 | 0.12 | Why? |
| Global Health | 4 | 2020 | 13911 | 0.12 | Why? |
| Physical Therapists | 1 | 2017 | 311 | 0.12 | Why? |
| Pneumococcal Vaccines | 1 | 2018 | 571 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.12 | Why? |
| Aged, 80 and over | 7 | 2018 | 88759 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.11 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.11 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.11 | Why? |
| Smokers | 1 | 2017 | 550 | 0.11 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.11 | Why? |
| Ireland | 1 | 2017 | 1456 | 0.11 | Why? |
| Fibrinogen | 1 | 2017 | 1048 | 0.11 | Why? |
| Consensus | 3 | 2021 | 6345 | 0.11 | Why? |
| Cohort Studies | 7 | 2021 | 36005 | 0.11 | Why? |
| Androstadienes | 1 | 2009 | 27 | 0.10 | Why? |
| Belgium | 1 | 2017 | 2064 | 0.10 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.10 | Why? |
| Fluticasone | 1 | 2009 | 65 | 0.10 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.10 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.10 | Why? |
| Italy | 3 | 2020 | 38444 | 0.10 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.10 | Why? |
| United States | 4 | 2020 | 46150 | 0.09 | Why? |
| Tomography, X-Ray Computed | 5 | 2019 | 25144 | 0.09 | Why? |
| Radiography | 1 | 2017 | 1576 | 0.09 | Why? |
| Cooperative Behavior | 1 | 2017 | 1216 | 0.09 | Why? |
| Interviews as Topic | 1 | 2018 | 1952 | 0.09 | Why? |
| Publishing | 1 | 2019 | 990 | 0.09 | Why? |
| General Practice | 1 | 2017 | 718 | 0.09 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.09 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.09 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.09 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.08 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2017 | 1881 | 0.08 | Why? |
| Lung Transplantation | 1 | 2018 | 1554 | 0.08 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
| Cough | 2 | 2017 | 4891 | 0.08 | Why? |
| Inflammation | 3 | 2017 | 13255 | 0.08 | Why? |
| Environmental Monitoring | 1 | 2018 | 3143 | 0.08 | Why? |
| Particulate Matter | 1 | 2018 | 3249 | 0.08 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.07 | Why? |
| Scotland | 2 | 2020 | 1119 | 0.07 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.07 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.07 | Why? |
| Lung Diseases | 1 | 2019 | 2361 | 0.07 | Why? |
| Health Resources | 1 | 2019 | 2592 | 0.07 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.07 | Why? |
| Spirometry | 2 | 2018 | 524 | 0.07 | Why? |
| Myocardium | 1 | 2017 | 2323 | 0.07 | Why? |
| Risk | 1 | 2017 | 5288 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.07 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.07 | Why? |
| France | 1 | 2020 | 12074 | 0.07 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.06 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.06 | Why? |
| South Australia | 1 | 2021 | 123 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2017 | 2662 | 0.06 | Why? |
| Animals | 4 | 2020 | 78931 | 0.06 | Why? |
| Risk Factors | 4 | 2018 | 71621 | 0.06 | Why? |
| Air Pollutants | 1 | 2018 | 3110 | 0.05 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.05 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
| Bronchoscopy | 2 | 2019 | 991 | 0.05 | Why? |
| Inflammatory Bowel Diseases | 1 | 2017 | 3209 | 0.05 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.05 | Why? |
| Antibodies, Fungal | 1 | 2018 | 49 | 0.05 | Why? |
| Lung Volume Measurements | 1 | 2018 | 115 | 0.05 | Why? |
| Sleep Medicine Specialty | 1 | 2019 | 76 | 0.05 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.04 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.04 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
| Fatty Acid-Binding Proteins | 1 | 2017 | 93 | 0.04 | Why? |
| Idiopathic Interstitial Pneumonias | 1 | 2017 | 36 | 0.04 | Why? |
| Pseudomonas | 1 | 2017 | 65 | 0.04 | Why? |
| Benzamides | 1 | 2020 | 421 | 0.04 | Why? |
| Papio | 1 | 2017 | 104 | 0.04 | Why? |
| Stress, Mechanical | 1 | 2017 | 143 | 0.04 | Why? |
| Pulmonary Ventilation | 1 | 2018 | 152 | 0.04 | Why? |
| Acute-Phase Reaction | 1 | 2017 | 116 | 0.04 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.04 | Why? |
| Liposomes | 1 | 2019 | 334 | 0.04 | Why? |
| Immunoglobulin Isotypes | 1 | 2018 | 308 | 0.04 | Why? |
| Meat | 1 | 2019 | 380 | 0.04 | Why? |
| Pleural Diseases | 1 | 2017 | 68 | 0.04 | Why? |
| Hospital Costs | 1 | 2019 | 274 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.04 | Why? |
| Geography, Medical | 1 | 2018 | 537 | 0.04 | Why? |
| Aspergillus | 1 | 2018 | 347 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.04 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.04 | Why? |
| Symptom Flare Up | 1 | 2019 | 432 | 0.04 | Why? |
| Analysis of Variance | 1 | 2018 | 950 | 0.03 | Why? |
| Neutrophil Activation | 1 | 2017 | 510 | 0.03 | Why? |
| Malaysia | 1 | 2018 | 1116 | 0.03 | Why? |
| In Vitro Techniques | 1 | 2017 | 1027 | 0.03 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.03 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Immunologic Deficiency Syndromes | 1 | 2017 | 368 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2017 | 657 | 0.03 | Why? |
| Delphi Technique | 1 | 2017 | 1257 | 0.03 | Why? |
| North America | 1 | 2017 | 1400 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Calcium | 1 | 2017 | 708 | 0.03 | Why? |
| Troponin T | 1 | 2017 | 771 | 0.03 | Why? |
| Terminology as Topic | 1 | 2017 | 546 | 0.03 | Why? |
| Health Expenditures | 1 | 2019 | 904 | 0.03 | Why? |
| Bronchi | 1 | 2018 | 1048 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Residence Characteristics | 1 | 2021 | 1927 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Asia | 1 | 2017 | 2399 | 0.03 | Why? |
| China | 1 | 2017 | 50654 | 0.02 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.02 | Why? |
| Poverty | 1 | 2021 | 2302 | 0.02 | Why? |
| Airway Management | 1 | 2019 | 1298 | 0.02 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.02 | Why? |
| Emotions | 1 | 2021 | 2418 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Singapore | 1 | 2018 | 3641 | 0.02 | Why? |
| Heart | 1 | 2017 | 1791 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| South Africa | 1 | 2017 | 3326 | 0.02 | Why? |
| England | 1 | 2019 | 5116 | 0.02 | Why? |
| Long-Term Care | 1 | 2019 | 2047 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2018 | 53120 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2019 | 2844 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Cytokines | 2 | 2017 | 15010 | 0.02 | Why? |
| Tracheostomy | 1 | 2018 | 1963 | 0.02 | Why? |
| Child | 3 | 2018 | 70012 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Critical Care | 2 | 2019 | 14081 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.02 | Why? |
| Dyspnea | 1 | 2017 | 3847 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2021 | 8495 | 0.02 | Why? |
| Germany | 1 | 2019 | 9196 | 0.02 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.02 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.02 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.02 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| India | 1 | 2017 | 11875 | 0.01 | Why? |
| Interleukin-6 | 1 | 2017 | 7522 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Respiratory Insufficiency | 1 | 2017 | 7301 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.01 | Why? |
| Intensive Care Units | 1 | 2017 | 29594 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |